Latest Ratios: P/E Ratio 12.3x · EV/EBITDA 6.3x · ROE 16.1%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $16.8B | $18.1B | $12.4B | $7.9B | $5.4B | $8.9B | $4.2B | $3.9B | $1.8B | $1.5B | $1.5B |
| Enterprise Value | $27.0B | $28.3B | $23.7B | $21.7B | $19.6B | $22.2B | $17.5B | $18.4B | $16.2B | $15.9B | $16.0B |
| P/E Ratio → | 12.34 | 12.83 | 3.86 | 13.23 | 12.87 | 9.70 | 10.65 | — | 16.02 | — | — |
| P/S Ratio | 0.79 | 0.85 | 0.60 | 0.39 | 0.28 | 0.46 | 0.24 | 0.21 | 0.10 | 0.08 | 0.08 |
| P/B Ratio | 1.94 | 2.01 | 1.45 | 1.44 | 1.17 | 2.08 | 1.47 | 1.98 | 0.85 | 0.63 | 0.42 |
| P/FCF | 6.62 | 7.13 | 11.07 | 4.88 | 16.80 | 9.75 | 1.48 | 6.98 | 4.12 | 3.09 | — |
| P/OCF | 4.73 | 5.10 | 6.04 | 3.34 | 4.98 | 5.66 | 1.25 | 3.19 | 1.70 | 1.27 | 2.64 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.33 | 1.15 | 1.06 | 1.02 | 1.14 | 0.99 | 1.00 | 0.88 | 0.83 | 0.82 |
| EV / EBITDA | 6.29 | 6.59 | 3.49 | 6.42 | 6.18 | 5.95 | 6.15 | 7.72 | 6.64 | 7.99 | 7.64 |
| EV / EBIT | 7.86 | 7.83 | 3.90 | 8.62 | 8.78 | 7.88 | 10.46 | 14.12 | 9.92 | 17.10 | 13.05 |
| EV / FCF | — | 11.20 | 21.20 | 13.37 | 61.10 | 24.34 | 6.11 | 32.72 | 37.49 | 32.15 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.3% | 82.3% | 39.7% | 38.0% | 36.8% | 37.3% | 35.3% | 36.3% | 36.4% | 35.4% | 36.4% |
| Operating Margin | 16.1% | 16.1% | 28.8% | 12.2% | 12.2% | 14.7% | 11.3% | 8.3% | 8.9% | 5.8% | 6.4% |
| Net Profit Margin | 6.6% | 6.6% | 15.5% | 3.0% | 2.1% | 4.7% | 2.3% | -1.2% | 0.6% | -3.7% | -1.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.1% | 16.1% | 45.5% | 12.1% | 9.3% | 25.6% | 16.4% | -10.5% | 4.6% | -23.9% | -5.7% |
| ROA | 4.8% | 4.8% | 11.2% | 2.2% | 1.5% | 3.3% | 1.6% | -0.9% | 0.5% | -2.9% | -0.8% |
| ROIC | 13.2% | 13.2% | 22.8% | 9.9% | 9.6% | 12.8% | 9.1% | 7.0% | 7.4% | 4.8% | 5.3% |
| ROCE | 13.8% | 13.8% | 24.7% | 10.9% | 10.3% | 12.8% | 9.6% | 8.2% | 8.7% | 5.6% | 6.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.47 | 1.47 | 1.68 | 2.72 | 3.27 | 3.68 | 5.44 | 7.42 | 7.04 | 6.21 | 4.39 |
| Debt / EBITDA | 3.06 | 3.06 | 2.11 | 4.44 | 4.75 | 4.20 | 5.52 | 6.18 | 6.08 | 7.53 | 7.27 |
| Net Debt / Equity | — | 1.15 | 1.32 | 2.50 | 3.09 | 3.12 | 4.59 | 7.28 | 6.84 | 5.96 | 4.18 |
| Net Debt / EBITDA | 2.39 | 2.39 | 1.67 | 4.08 | 4.48 | 3.56 | 4.66 | 6.07 | 5.91 | 7.22 | 6.93 |
| Debt / FCF | — | 4.07 | 10.13 | 8.49 | 44.30 | 14.60 | 4.63 | 25.74 | 33.37 | 29.06 | — |
| Interest Coverage | 4.41 | 4.41 | 7.35 | 2.79 | 2.51 | 3.05 | 1.67 | 1.32 | 1.63 | 0.90 | 1.25 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.76 | 1.76 | 1.78 | 1.51 | 1.34 | 1.38 | 1.47 | 1.21 | 1.20 | 1.29 | 1.30 |
| Quick Ratio | 1.68 | 1.68 | 1.70 | 1.42 | 1.25 | 1.31 | 1.40 | 1.13 | 1.12 | 1.22 | 1.22 |
| Cash Ratio | 0.65 | 0.65 | 0.70 | 0.26 | 0.19 | 0.46 | 0.50 | 0.06 | 0.11 | 0.14 | 0.18 |
| Asset Turnover | — | 0.72 | 0.71 | 0.73 | 0.71 | 0.71 | 0.65 | 0.79 | 0.82 | 0.82 | 0.79 |
| Inventory Turnover | 10.86 | 10.86 | 36.00 | 31.00 | 29.94 | 31.82 | 31.00 | 37.95 | 38.21 | 42.85 | 38.28 |
| Days Sales Outstanding | — | 43.93 | 53.94 | 60.47 | 65.90 | 61.93 | 69.34 | 64.47 | 61.65 | 57.57 | 63.84 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.1% | 7.8% | 25.9% | 7.6% | 7.8% | 10.3% | 9.4% | — | 6.2% | — | — |
| FCF Yield | 15.1% | 14.0% | 9.0% | 20.5% | 6.0% | 10.3% | 67.6% | 14.3% | 24.3% | 32.3% | — |
| Buyback Yield | 8.6% | 8.0% | 5.4% | 2.5% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 8.6% | 8.0% | 5.4% | 2.5% | 4.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $91M | $98M | $105M | $111M | $109M | $106M | $103M | $104M | $101M | $99M |
Labor cost inflation volatility
Based on current market data, Tenet trades at a forward P/E of 10.49, which appears to undervalue the high-growth USPI ambulatory platform relative to pure-play peers like Surgery Partners, suggesting the market continues to apply a conglomerate discount due to the legacy hospital segment's inherent operational volatility.
The current valuation multiples, including an EV/EBITDA of 6.24, reflect a cautious market stance that likely prioritizes the capital-intensive nature of hospital operations over the superior margins of the ambulatory business. Investors should monitor whether the ongoing divestiture of non-core hospital assets triggers a re-rating as the company's revenue mix shifts toward the higher-multiple ASC model.
As reported in recent financial statements, Tenet's ROIC has remained largely stagnant, hovering between 2.9% and 4.7% over the last ten quarters, which indicates that the company's aggressive acquisition strategy has yet to yield a compounding return on invested capital that exceeds its cost of capital.
The persistent gap between ROIC and historical sector benchmarks suggests that the significant goodwill on the balance sheet continues to dilute capital efficiency. While the shift toward the USPI platform is intended to improve returns, the current data implies that the heavy asset base of the hospital segment remains a drag on overall capital productivity.
According to quarterly filings, Tenet's cash conversion cycle has displayed extreme variance, swinging from a negative 42 days in 2025Q1 to a positive 33 days in 2025Q4, highlighting significant instability in the company's ability to manage its working capital effectively across its diverse service segments.
The erratic nature of the CCC, driven by fluctuations in days sales outstanding and payables, suggests that the company's operational efficiency is highly sensitive to the timing of supplemental government payments and internal restructuring. This volatility warrants further investigation into whether the company's revenue cycle management processes are sufficiently integrated to provide predictable cash flow generation.
Based on reported figures, Tenet has successfully reduced its debt-to-equity ratio from 2.72 in 2023Q4 to 1.49 in 2026Q1, signaling a meaningful effort to improve financial flexibility, although the debt-to-EBITDA ratio remains elevated at 11.89, indicating that debt service remains a significant burden on core operating cash flows.
While the reduction in the debt-to-equity ratio is a positive development, the high debt-to-EBITDA level suggests that the company remains vulnerable to interest rate fluctuations and potential earnings compression. Investors should monitor the interest coverage ratio, which has shown inconsistency, to ensure that the company maintains sufficient headroom to meet its obligations during periods of operational stress.
As indicated by the provided financial data, the consolidated net margin is frequently misapplied by analysts as a proxy for Tenet's core earning power, failing to account for the significant non-controlling interests in the USPI segment that distort the true profitability attributable to Tenet shareholders.
Relying on consolidated net margins obscures the underlying performance of the high-margin ambulatory business by blending it with the lower-margin hospital operations and the impact of minority partner distributions. Analysts should instead focus on segment-level operating margins and adjusted EBITDA to better assess the company's true operational health and the value creation potential of its ASC platform.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying THC stock.
Tenet Healthcare Corporation's current P/E ratio is 12.3x. The historical average is 18.7x. This places it at the 28th percentile of its historical range.
Tenet Healthcare Corporation's current EV/EBITDA is 6.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.7x.
Tenet Healthcare Corporation's return on equity (ROE) is 16.1%. The historical average is -0.9%.
Based on historical data, Tenet Healthcare Corporation is trading at a P/E of 12.3x. This is at the 28th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Tenet Healthcare Corporation has 82.3% gross margin and 16.1% operating margin. Operating margin between 10-20% is typical for established companies.
Tenet Healthcare Corporation's Debt/EBITDA ratio is 3.1x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.